Molecular phenotyping of clinical AKI with novel urinary biomarkers.
New Haven, United States. In Am J Physiol Renal Physiol, Oct 2015
We will discuss two AKI biomarkers, neutrophil gelatinase-associated lipocalin (NGAL) and breast regression protein-39 (BRP-39)/YKL-40, that exemplify the need to characterize the complexity of the biological meaning behind the biomarker, beyond elevated levels reporting on tissue injury.
Chitinase-3-like-1/YKL-40 as marker of circulating tumor cells.
Vienna, Austria. In Transl Lung Cancer Res, Jun 2015
Permanent CTC cultures of different patients shared secretion of chitinase-3-like-1 (CHI3L1)/YKL-40, known to be upregulated in a range of tumor entities and to be associated with increased metastasis and decreased survival.
OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease.
Torino, Italy. In Mediators Inflamm, Dec 2014
In this review, we focus on molecular mechanisms linking OSAS to NAFLD, including hypoxia inducible factor (HIF), nuclear factor kappa B (NF-κB), YKL-40, unfolded protein response, and hypoxic adipose tissue inflammation, which all could provide novel potential therapeutic approaches for the management of NAFLD patients with OSAS.
Biomarkers of progression of chronic obstructive pulmonary disease (COPD).
Brisbane, Australia. In J Thorac Dis, Nov 2014
Examples of peripheral blood biological markers (biomarkers) include those associated with lung function (reduced CC-16), emphysema severity (increased adiponectin, reduced sRAGE), exacerbations and mortality [increased CRP, fibrinogen, leukocyte count, IL-6, IL-8, and tumor necrosis factor α (TNF-α)] including increased YKL-40 with mortality.